
Researchers employed ultra-high-performance liquid chromatography (UHPLC) with orbital trap mass spectrometry and liquid chromatography-tandem mass spectrometry (LC-MS/MS) to conduct a multi-omics analysis of patients with coronary heart disease (CHD). The study identified significant gut microbiota dysbiosis, alongside 32 differentially expressed metabolites and 38 differentially expressed proteins. These findings reveal distinct metabolic pathway alterations that could serve as potential diagnostic biomarkers and novel therapeutic targets for early CHD detection and intervention.
























